Accelerate biotechnology

Blog: Accelerating viral vector and vaccine development: beware the pitfalls of scale-up

You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in human subjects…or are you? Whether you are developing a viral vaccine, cancer vaccine, oncolytic virus, gene therapy or other viral vector application, the choices you…


Article: How we prepare for the next virus outbreak

Recently, Menzo Havenga (CEO at Batavia Biosciences) was interviewed by the online magazine named “Startup Info”. This magazine is devoted to informing its readers on the booming startup ecosystem worldwide. The magazine desires to provide entrepreneurs who are looking for inspiration with relevant information, tips, and tricks. In the interview, Menzo elaborates on the impact…


Scientific publication: Process development for cost-effective, liquid rotavirus vaccine

We are proud to announce that our recent manuscript has been accepted for publication in the journal Vaccine. The manuscript describes the development of a low-cost manufacturing process for a novel human rotavirus vaccine.  Rotavirus infection, associated with severe vomiting and diarrhea, is a leading cause of mortality in young children. Despite the presence of…


Article: Gene therapies push AAV vector production

Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). All platforms have their own advantages over one of the others. The recent successes with AAV and lentivirus give these vectors a boost in development. In combination with the fact that they are…


Article: Gene therapy developers see an expanded viral toolbox

There are still many challenges in gene therapy analytics and manufacturing according to gene therapy developers. Our Global Technical Director, Alfred Luitjens was interviewed on this topic by Genetic Engineering & Biotechnology News. The interview was in response to his presentation on the manufacturing of a lentiviral vector for a gene therapy against RAG1-SCID at…

COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.